Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 3
2019 7
2020 10
2021 4
2022 5
2023 28
2024 34
2025 47
2026 38

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Results by year

Filters applied: . Clear all
Page 1
AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis.
Singh S, Loftus EV Jr, Limketkai BN, Haydek JP, Agrawal M, Scott FI, Ananthakrishnan AN; AGA Clinical Guidelines Committee. Electronic address: clinicalpractice@gastro.org. Singh S, et al. Gastroenterology. 2024 Dec;167(7):1307-1343. doi: 10.1053/j.gastro.2024.10.001. Gastroenterology. 2024. PMID: 39572132 Free PMC article.
BACKGROUND & AIMS: This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacological management of moderate-to-severe ulcerative colitis (UC). METHODS: A multidisciplinary panel of content experts an …
BACKGROUND & AIMS: This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the phar …
Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience.
Friedberg S, Choi D, Hunold T, Choi NK, Garcia NM, Picker EA, Cohen NA, Cohen RD, Dalal SR, Pekow J, Sakuraba A, Krugliak Cleveland N, Rubin DT. Friedberg S, et al. Clin Gastroenterol Hepatol. 2023 Jul;21(7):1913-1923.e2. doi: 10.1016/j.cgh.2023.03.001. Epub 2023 Mar 8. Clin Gastroenterol Hepatol. 2023. PMID: 36898598 Free PMC article.
BACKGROUND & AIMS: Upadacitinib is a novel selective Janus kinase 1 inhibitor that has shown efficacy in the treatment of moderate to severe ulcerative colitis (UC) and Crohn's disease (CD), and has received Food and Drug Administrati …
BACKGROUND & AIMS: Upadacitinib is a novel selective Janus kinase 1 inhibitor that has shown efficacy in the treatment of moderat …
Persistence, Effectiveness, and Safety of Upadacitinib in Crohn's Disease and Ulcerative Colitis in Real Life: Results From a Spanish Nationwide Study (Ureal Study).
García MJ, Brenes Y, Vicuña M, Bermejo F, Sierra-Ausín M, Vicente R, Arroyo MT, Martínez Montiel P, Villoria A, Ferrer JÁ, Hernandez V, Piñero A, Carrillo-Palau M, Martín-Arranz MD, Miranda-Bautista J, Pajares R, Arranz Hernández L, Bejarano A, Guardiola J, Iyo E, Muñoz-Villafranca C, Talavera A, Alonso-Galán H, Barreiro-de Acosta M, Bosca-Watts M, Vázquez Rey T, Echarri A, Rodríguez-Grau MDC, Gutiérrez A, Huguet JM, López-Martín MC, Mesonero F, Pérez-Martínez I, Plaza R, Ramírez de la Piscina P, Gisbert JP, Chaparro M. García MJ, et al. Am J Gastroenterol. 2024 Nov 26;120(7):1593-1604. doi: 10.14309/ajg.0000000000003243. Am J Gastroenterol. 2024. PMID: 39588977
INTRODUCTION: Real-world data on the effectiveness of upadacitinib for inflammatory bowel disease (IBD) are limited. To assess upadacitinib persistence, effectiveness, and safety in a real-world scenario. ...Clinical effectiveness was assessed based on partia …
INTRODUCTION: Real-world data on the effectiveness of upadacitinib for inflammatory bowel disease (IBD) are limited. To assess …
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.
Ananthakrishnan AN, Murad MH, Scott FI, Agrawal M, Haydek JP, Limketkai BN, Loftus EV Jr, Singh S. Ananthakrishnan AN, et al. Gastroenterology. 2024 Dec;167(7):1460-1482. doi: 10.1053/j.gastro.2024.07.046. Epub 2024 Oct 18. Gastroenterology. 2024. PMID: 39425738 Free PMC article.
BACKGROUND & AIMS: We performed an updated systematic review and network meta-analysis to inform the 2024 American Gastroenterological Association (AGA) Clinical Guidelines on the management of moderate-to-severe ulcerative colitis (UC). METHODS: We searched mul …
BACKGROUND & AIMS: We performed an updated systematic review and network meta-analysis to inform the 2024 American Gastroenterological A …
Systematic Review with Meta-analysis: Efficacy and Safety of Upadacitinib in Managing Moderate-to-Severe Crohn's Disease and Ulcerative Colitis.
Niu C, Zhang J, Napel M, Boppana LKT, Anas H, Jadhav N, Dunnigan K, Okolo PI 3rd. Niu C, et al. Clin Drug Investig. 2024 Jun;44(6):371-385. doi: 10.1007/s40261-024-01364-0. Epub 2024 May 23. Clin Drug Investig. 2024. PMID: 38777970
Peer-reviewed articles that reported data on the effects of upadacitinib in adult patients with Crohn's disease and ulcerative colitis were included based on established inclusion and exclusion criteria. ...The pooled clinical response ra …
Peer-reviewed articles that reported data on the effects of upadacitinib in adult patients with Crohn's disease …
Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study.
Yerushalmy-Feler A, Spencer EA, Dolinger MT, Suskind DL, Mitrova K, Hradsky O, Conrad MA, Kelsen JR, Uhlig HH, Tzivinikos C, Ancona S, Wlazlo M, Hackl L, Shouval DS, Bramuzzo M, Urlep D, Olbjorn C, D'Arcangelo G, Pujol-Muncunill G, Yogev D, Kang B, Gasparetto M, Rungø C, Kolho KL, Hojsak I, Norsa L, Rinawi F, Sansotta N, Magen Rimon R, Granot M, Scarallo L, Trindade E, Velasco Rodríguez-Belvís M, Turner D, Cohen S. Yerushalmy-Feler A, et al. J Crohns Colitis. 2025 May 8;19(5):jjae182. doi: 10.1093/ecco-jcc/jjae182. J Crohns Colitis. 2025. PMID: 39605286 Free PMC article.
BACKGROUND AND AIMS: Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as an induction therapy i …
BACKGROUND AND AIMS: Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory …
Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning.
Fudman DI, McConnell RA, Ha C, Singh S. Fudman DI, et al. Clin Gastroenterol Hepatol. 2025 Feb;23(3):454-468. doi: 10.1016/j.cgh.2024.06.050. Epub 2024 Aug 13. Clin Gastroenterol Hepatol. 2025. PMID: 39147217 Free PMC article. Review.
These include the oral small molecule drugs Janus kinase inhibitors (including upadacitinib, approved for Crohn's disease and ulcerative colitis [UC], and tofacitinib, approved for UC) and sphingosphine 1-phosphate receptor modulators (oz …
These include the oral small molecule drugs Janus kinase inhibitors (including upadacitinib, approved for Crohn's di …
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
Vermeire S, Danese S, Zhou W, Ilo D, Klaff J, Levy G, Yao X, Chen S, Sanchez Gonzalez Y, Hébuterne X, Lindsay JO, Higgins PDR, Cao Q, Nakase H, Colombel JF, Loftus EV Jr, Panaccione R. Vermeire S, et al. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):976-989. doi: 10.1016/S2468-1253(23)00208-X. Epub 2023 Sep 9. Lancet Gastroenterol Hepatol. 2023. PMID: 37683686 Clinical Trial.
For safety, 746 patients were analysed, representing 552.9 patient-years of exposure; the most common grade 3-4 treatment-emergent adverse events were worsening of ulcerative colitis in nine (4%) patients with placebo, and COVID-19 pneumonia and cryptococcal pneumon …
For safety, 746 patients were analysed, representing 552.9 patient-years of exposure; the most common grade 3-4 treatment-emergent adverse e …
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study.
Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S. Panaccione R, et al. Lancet Gastroenterol Hepatol. 2025 Jun;10(6):507-519. doi: 10.1016/S2468-1253(25)00017-2. Lancet Gastroenterol Hepatol. 2025. PMID: 40347957 Free article. Clinical Trial.
BACKGROUND: The U-ACTIVATE long-term extension study aims to evaluate the long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis. Here, we report interim results after 3 years of total treatment. ...INT …
BACKGROUND: The U-ACTIVATE long-term extension study aims to evaluate the long-term efficacy and safety of upadacitinib in patients w …
156 results